Gallic Acid Induces Apoptosis in Oral Squamous Cell Carcinoma via PI3K/AKT/mTOR Pathway Inhibition and PTEN

Sanaz Helli1, Armin Heidari1, Armin Tafvizi1

  • 1Department of Oral Medicine, TaMS.C., Islamic Azad University, Tabriz, Iran (the Islamic Republic of).

Drug Research
|November 26, 2025
PubMed

Insights

Gallic acid effectively reduced oral cancer cell viability by inhibiting the PI3K/AKT/mTOR pathway. This natural compound also activated apoptosis, showing promise for oral cancer targeted therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Natural Product Chemistry

Background:

  • Oral squamous cell carcinoma (OSCC) presents significant challenges due to drug resistance and high mortality.
  • The Phosphatidylinositol 3-kinase/Protein kinase B/Mammalian target of rapamycin (PI3K/AKT/mTOR) pathway is critical for cancer cell survival, growth, and metastasis.
  • Targeting the PI3K/AKT/mTOR pathway offers a promising strategy for OSCC treatment.

Purpose of the Study:

  • To investigate the antitumor effects of gallic acid on OSCC CAL-27 cells.
  • To elucidate the impact of gallic acid on the PI3K/AKT/mTOR signaling pathway.
  • To assess the induction of apoptosis by gallic acid in OSCC cells.

Main Methods:

  • CAL-27 cells were treated with varying concentrations of gallic acid.
  • Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
  • Gene and protein expression (PI3K/AKT/mTOR pathway, apoptosis markers) were analyzed via quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) and Western blot.
  • Caspase-3/7 activity and apoptosis levels were quantified using fluorometric and enzyme-linked immunosorbent assay (ELISA) methods.

Main Results:

  • Gallic acid demonstrated a dose- and time-dependent reduction in OSCC cell viability.
  • Gallic acid treatment led to decreased expression of PI3K, AKT, and mTOR, and increased PTEN expression.
  • Upregulation of Bax expression and enhanced caspase activity confirmed gallic acid-induced apoptosis.

Conclusions:

  • Gallic acid exhibits potent anticancer properties against OSCC cells.
  • Inhibition of the PI3K/AKT/mTOR pathway and activation of apoptotic pathways are key mechanisms of gallic acid's action.
  • Gallic acid holds potential as a therapeutic agent for oral cancer, warranting further preclinical investigation.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K